Eli Lilly And Stock Z Score

LLY Stock

USD 732.20 13.49 1.81%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Eli Lilly Piotroski F Score and Eli Lilly Valuation analysis.

At this time, Eli Lilly's Capital Expenditures is fairly stable compared to the past year. Invested Capital is likely to rise to 2.46 in 2024, whereas Capital Stock is likely to drop slightly above 544.7 M in 2024. At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Reconciled Depreciation is likely to rise to about 1.6 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 994.5 M in 2024.

Eli Lilly and Company Z Score Analysis

Eli Lilly's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Eli Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Eli Lilly is extremely important. It helps to project a fair market value of Eli Stock properly, considering its historical fundamentals such as Z Score. Since Eli Lilly's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eli Lilly's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eli Lilly's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Debt	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Good Will	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.11	0.83	0.08	0.94	0.95	0.97	0.74	0.72	0.96	-0.27	-0.68	-0.68	0.85	0.59	0.87	0.61	0.8	-0.49	0.63	0.78	-0.07	0.74	-0.34	0.42	-0.59
Total Stockholder Equity	0.11		-0.34	0.97	-0.1	-0.19	0.09	-0.18	0.02	0.03	0.75	0.56	0.56	-0.39	-0.1	0.26	-0.1	-0.12	0.72	-0.54	-0.35	0.74	-0.12	0.27	0.3	0.18
Net Debt	0.83	-0.34		-0.4	0.93	0.93	0.77	0.83	0.73	0.91	-0.58	-0.92	-0.92	0.94	0.54	0.65	0.67	0.93	-0.73	0.8	0.86	-0.41	0.8	-0.66	0.41	-0.84
Retained Earnings	0.08	0.97	-0.4		-0.18	-0.22	0.06	-0.21	-0.05	-0.03	0.81	0.62	0.62	-0.42	-0.03	0.21	-0.08	-0.22	0.71	-0.57	-0.41	0.8	-0.17	0.38	0.16	0.29
Net Receivables	0.94	-0.1	0.93	-0.18		0.96	0.92	0.78	0.74	0.97	-0.48	-0.83	-0.83	0.92	0.51	0.79	0.59	0.9	-0.59	0.74	0.85	-0.27	0.8	-0.51	0.51	-0.74
Total Liab	0.95	-0.19	0.93	-0.22	0.96		0.93	0.8	0.69	0.94	-0.49	-0.84	-0.84	0.96	0.62	0.79	0.66	0.82	-0.71	0.8	0.89	-0.29	0.76	-0.43	0.33	-0.64
Total Current Assets	0.97	0.09	0.77	0.06	0.92	0.93		0.61	0.74	0.91	-0.27	-0.62	-0.62	0.82	0.53	0.84	0.53	0.72	-0.45	0.61	0.76	-0.07	0.78	-0.18	0.44	-0.5
Intangible Assets	0.74	-0.18	0.83	-0.21	0.78	0.8	0.61		0.37	0.79	-0.4	-0.77	-0.77	0.83	0.52	0.64	0.79	0.79	-0.71	0.75	0.72	-0.17	0.45	-0.71	0.19	-0.68
Short Term Debt	0.72	0.02	0.73	-0.05	0.74	0.69	0.74	0.37		0.77	-0.18	-0.51	-0.51	0.56	0.26	0.51	0.37	0.75	-0.19	0.31	0.5	-0.06	0.95	-0.28	0.65	-0.73
Accounts Payable	0.96	0.03	0.91	-0.03	0.97	0.94	0.91	0.79	0.77		-0.34	-0.75	-0.75	0.87	0.54	0.81	0.64	0.91	-0.5	0.64	0.78	-0.14	0.81	-0.52	0.53	-0.77
Short Term Investments	-0.27	0.75	-0.58	0.81	-0.48	-0.49	-0.27	-0.4	-0.18	-0.34		0.78	0.78	-0.66	-0.24	-0.16	-0.2	-0.4	0.75	-0.73	-0.67	0.88	-0.26	0.42	-0.03	0.35
Capital Stock	-0.68	0.56	-0.92	0.62	-0.83	-0.84	-0.62	-0.77	-0.51	-0.75	0.78		1.0	-0.92	-0.48	-0.46	-0.53	-0.8	0.85	-0.86	-0.85	0.66	-0.61	0.61	-0.17	0.69
Common Stock	-0.68	0.56	-0.92	0.62	-0.83	-0.84	-0.62	-0.77	-0.51	-0.75	0.78	1.0		-0.92	-0.48	-0.46	-0.53	-0.8	0.85	-0.86	-0.85	0.66	-0.61	0.61	-0.17	0.69
Long Term Debt	0.85	-0.39	0.94	-0.42	0.92	0.96	0.82	0.83	0.56	0.87	-0.66	-0.92	-0.92		0.63	0.7	0.68	0.8	-0.84	0.91	0.93	-0.47	0.68	-0.49	0.25	-0.62
Treasury Stock	0.59	-0.1	0.54	-0.03	0.51	0.62	0.53	0.52	0.26	0.54	-0.24	-0.48	-0.48	0.63		0.55	0.64	0.41	-0.53	0.56	0.58	-0.19	0.36	-0.14	0.03	-0.22
Property Plant Equipment	0.87	0.26	0.65	0.21	0.79	0.79	0.84	0.64	0.51	0.81	-0.16	-0.46	-0.46	0.7	0.55		0.68	0.65	-0.38	0.63	0.78	0.02	0.54	-0.34	0.5	-0.44
Good Will	0.61	-0.1	0.67	-0.08	0.59	0.66	0.53	0.79	0.37	0.64	-0.2	-0.53	-0.53	0.68	0.64	0.68		0.62	-0.62	0.7	0.69	-0.11	0.48	-0.45	0.28	-0.5
Current Deferred Revenue	0.8	-0.12	0.93	-0.22	0.9	0.82	0.72	0.79	0.75	0.91	-0.4	-0.8	-0.8	0.8	0.41	0.65	0.62		-0.49	0.63	0.71	-0.22	0.79	-0.71	0.59	-0.92
Net Tangible Assets	-0.49	0.72	-0.73	0.71	-0.59	-0.71	-0.45	-0.71	-0.19	-0.5	0.75	0.85	0.85	-0.84	-0.53	-0.38	-0.62	-0.49		-0.92	-0.81	0.66	-0.36	0.46	0.15	0.39
Long Term Debt Total	0.63	-0.54	0.8	-0.57	0.74	0.8	0.61	0.75	0.31	0.64	-0.73	-0.86	-0.86	0.91	0.56	0.63	0.7	0.63	-0.92		0.95	-0.59	0.46	-0.5	0.16	-0.46
Capital Surpluse	0.78	-0.35	0.86	-0.41	0.85	0.89	0.76	0.72	0.5	0.78	-0.67	-0.85	-0.85	0.93	0.58	0.78	0.69	0.71	-0.81	0.95		-0.55	0.61	-0.5	0.32	-0.55
Long Term Investments	-0.07	0.74	-0.41	0.8	-0.27	-0.29	-0.07	-0.17	-0.06	-0.14	0.88	0.66	0.66	-0.47	-0.19	0.02	-0.11	-0.22	0.66	-0.59	-0.55		-0.17	0.3	0.1	0.21
Short Long Term Debt	0.74	-0.12	0.8	-0.17	0.8	0.76	0.78	0.45	0.95	0.81	-0.26	-0.61	-0.61	0.68	0.36	0.54	0.48	0.79	-0.36	0.46	0.61	-0.17		-0.3	0.62	-0.75
Cash And Equivalents	-0.34	0.27	-0.66	0.38	-0.51	-0.43	-0.18	-0.71	-0.28	-0.52	0.42	0.61	0.61	-0.49	-0.14	-0.34	-0.45	-0.71	0.46	-0.5	-0.5	0.3	-0.3		-0.31	0.82
Net Invested Capital	0.42	0.3	0.41	0.16	0.51	0.33	0.44	0.19	0.65	0.53	-0.03	-0.17	-0.17	0.25	0.03	0.5	0.28	0.59	0.15	0.16	0.32	0.1	0.62	-0.31		-0.56
Net Working Capital	-0.59	0.18	-0.84	0.29	-0.74	-0.64	-0.5	-0.68	-0.73	-0.77	0.35	0.69	0.69	-0.62	-0.22	-0.44	-0.5	-0.92	0.39	-0.46	-0.55	0.21	-0.75	0.82	-0.56

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Eli Lilly

Based on the company's disclosures, Eli Lilly and has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The z score for all United States stocks is 100.0% higher than that of the company.

Eli Lilly ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.

Environment Score

Governance Score

Social Score

Eli Lilly Institutional Holders

Institutional Holdings refers to the ownership stake in Eli Lilly that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eli Lilly's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eli Lilly's value.

		Shares
Geode Capital Management, Llc	2023-12-31	16 M
Morgan Stanley - Brokerage Accounts	2023-12-31	12.7 M
Wellington Management Company Llp	2023-12-31	11.8 M
Norges Bank	2023-12-31	10.3 M
Bank Of America Corp	2023-12-31	9.9 M
Goldman Sachs Group Inc	2023-12-31	9.4 M
Northern Trust Corp	2023-12-31	9.1 M
Jennison Associates Llc	2023-12-31	7.6 M
Capital Research Global Investors	2023-12-31	7.6 M
Lilly Endowment Inc	2023-12-31	99.8 M
Vanguard Group Inc	2023-12-31	71.6 M

Eli Fundamentals

	Return On Equity	0.48
	Return On Asset	0.12
	Profit Margin	0.15 %
	Operating Margin	0.34 %
	Current Valuation	682.62 B
	Shares Outstanding	950.77 M
	Shares Owned By Insiders	0.16 %
	Shares Owned By Institutions	84.30 %
	Number Of Shares Shorted	5.42 M
	Price To Earning	54.92 X
	Price To Book	66.34 X
	Price To Sales	20.94 X
	Revenue	34.12 B
	Gross Profit	21.91 B
	EBITDA	12.46 B
	Net Income	5.24 B
	Cash And Equivalents	2.07 B
	Cash Per Share	2.97 X
	Total Debt	25.23 B
	Debt To Equity	1.58 %
	Current Ratio	1.13 X
	Book Value Per Share	11.98 X
	Cash Flow From Operations	4.24 B
	Short Ratio	1.82 X
	Earnings Per Share	5.78 X
	Price To Earnings To Growth	1.43 X
	Target Price	826.94
	Number Of Employees	43 K
	Beta	0.37
	Market Capitalization	708.98 B
	Total Asset	64.01 B
	Retained Earnings	10.31 B
	Working Capital	(1.57 B)
	Current Asset	12.57 B
	Current Liabilities	8.23 B
	Annual Yield	0.01 %
	Five Year Return	1.83 %
	Net Asset	64.01 B
	Last Dividend Paid	4.52

About Eli Lilly Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:

How To Invest In Eli

Details

Is Eli Stock a good investment?

Details

What is Eli Lilly's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Eli Lilly Piotroski F Score and Eli Lilly Valuation analysis.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Commodity Directory Find actively traded commodities issued by global exchanges
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency

Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.13

Dividend Share

4.52

Earnings Share

5.78

Revenue Per Share

37.908

Quarterly Revenue Growth

0.281

The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eli Lilly And Stock Z Score

Eli Lilly and Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Eli Z Score Driver Correlations

Eli Lilly ESG Sustainability

Eli Lilly Institutional Holders

Eli Fundamentals

About Eli Lilly Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Eli Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY